Literature DB >> 8619763

Risk factors for central retinal vein occlusion. The Eye Disease Case-Control Study Group.

.   

Abstract

OBJECTIVE: To identify possible risk factors for central retinal vein occlusion (CRVO).
DESIGN: Between May 1, 1986, and December 31, 1990, 258 patients with CRVO and 1142 controls were identified at five clinical centers. Data were obtained through interviews, clinical examinations, and laboratory analyses of blood specimens.
RESULTS: An increased risk of CRVO was found in persons with systemic hypertension, diabetes mellitus, and open-angle glaucoma. Risk of CRVO decreased with increasing levels of physical activity and increasing levels of alcohol consumption. In women, risk of occlusion decreased with use of postmenopausal estrogens and increased with higher erythrocyte sedimentation rates. Cardiovascular disease, electrocardiographic abnormalities, history of treatment of diabetes mellitus, higher blood glucose levels, lower albumin-globulin ratios, and higher alpha-globulin levels were associated with increased risk only for ischemic CRVO. Systemic hypertension was associated with increased risk for ischemic and nonischemic CRVO, but odds ratios were greater for the ischemic type.
CONCLUSIONS: Our results suggest a cardiovascular risk profile for persons with CRVO, in particular, patients with the ischemic type. The findings reinforce recommendations to diagnose and treat systemic hypertension, advise patients to increase physical exercise, and consider use of exogenous estrogens in postmenopausal women.

Entities:  

Mesh:

Year:  1996        PMID: 8619763

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  95 in total

1.  Influence of factor V Leiden on the development of neovascularisation secondary to central retinal vein occlusion.

Authors:  C Hvarfner; A Hillarp; J Larsson
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

2.  Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10.

Authors:  Ingrid U Scott; Paul C VanVeldhuisen; Neal L Oden; Michael S Ip; Barbara A Blodi; Mary Elizabeth Hartnett; Geoff Cohen
Journal:  Ophthalmology       Date:  2011-02       Impact factor: 12.079

3.  Retinal vein pulsation predicts increasing optic disc excavation.

Authors:  Marcelo T Nicolela
Journal:  Br J Ophthalmol       Date:  2007-04       Impact factor: 4.638

4.  [Thrombophilic and systemic risk factors in patients with retinal vein occlusion].

Authors:  C Kuhli-Hattenbach; W Miesbach; I Scharrer; L-O Hattenbach
Journal:  Ophthalmologe       Date:  2011-02       Impact factor: 1.059

Review 5.  The future of glaucoma clinics.

Authors:  A M S Morley; I Murdoch
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

Review 6.  Role of Lipids in Retinal Vascular and Macular Disorders.

Authors:  Gunjan Prakash; Rachit Agrawal; Tanie Natung
Journal:  Indian J Clin Biochem       Date:  2016-03-08

7.  Efficacy of intravitreal triamcinolone for macular oedema due to CRVO after anti-androgen therapy for hirsutism in a young monocular female.

Authors:  Hassan Al-Dhibi; Imtiaz A Chaudhry; Annoud Al-Saati; Farrukh A Shamsi
Journal:  Br J Ophthalmol       Date:  2007-11       Impact factor: 4.638

8.  Influence of diabetes and diabetes type on anatomic and visual outcomes following central rein vein occlusion.

Authors:  J G Santiago; S Walia; J K Sun; J D Cavallerano; Z A Haddad; L P Aiello; P S Silva
Journal:  Eye (Lond)       Date:  2014-02-14       Impact factor: 3.775

9.  Cavernous sinus thrombosis elicited by a central retinal vein venous stasis retinopathy.

Authors:  Marc Zaninetti; Alexandros N Stangos; German Abdo; Constantin J Pournaras
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-09       Impact factor: 3.117

10.  Measurement of lamina and prelaminar thicknesses of both eyes in patients with unilateral branch retinal vein occlusion.

Authors:  Yengwoo Son; Seungwoo Lee; Jongyeop Park
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-09-14       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.